tbuckley/cabot-search huggingface dataset:
Nagoya Journal of Medical Science
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase II trial of motexafin gadolinium (MGd) for treatment of metastatic renal cell carcinoma (MRCC)
Authors: J. Jac, J. Hernandez, S.-C. Phan, R. J. Amato
Journal: Journal of Clinical Oncology (2005)

4724 Background: MGd inhibits thioredoxin reductase. Thioredoxin is implicated in activation of hypoxia-inducible factor-1 alpha, which is overexpressed in >85% of renal cell carcinomas (RCC). We evaluated safety and anti-tumor activity of MGd in patients (pts) with progressive MRCC. Methods: Eligibility included: measurable MRCC, normal organ/marrow function, Zubrod performance status (ZPS) ≤2, life expectancy ≥12 weeks, ≤2 prior therapies, no active CNS involvement. MGd was infused intravenously over 30 minutes at 5mg/kg on days 1–5 and 15–19 of each 28-day cycle. Evaluation was performed after every 3 cycles. RECIST criteria were utilized to determine response rate. Results: Twenty-two evaluable pts were enrolled 17male/5 female, median age 63 years (range 38–76). All pts had histologic confirmed RCC; 9 pts had clear cell carcinoma, 9 pts with predominant clear cell carcinoma component, 2 pts with papillary and 1 pt with collecting duct. Twenty-one pts received prior systemic therapy, median 2 treatments (range 1–2). Fourteen pts had ZPS of 0, 7 pts had ZPS of 1, and one pt had ZPS of 2. All pts had progressive MRCC. Sites of disease included: lung, nodal, bone, adrenal, kidney and liver. Six pts had 1 metastatic site, 5 pts had 2 and 11 pts had 3 or more. 15 pts have completed at least 12 weeks of therapy. Five pts progressed within 3 months. One pt had partial response of lung metastasis but progressed in the CNS. One pt is too early for re-evaluation. Five pts are continuing to receive MGd therapy. 8 pts were stable for 3 months; 2 pts were stable for 6 or more months. Grade 1/2 toxicity consisted of: skin discoloration, fatigue, nausea, and headache. Grade 3/4 toxicity consisted of: blisters of the digits and hypophosphatemia.Conclusions: MGd was well tolerated and stabilization of disease was observed in patients with progressive disease. These preliminary results show promise for MGd in the previously treated MRCC population Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pharmacyclics
Biochemical diagnosis of alcoholism. A test of the discriminating capabilities of gamma-glutamyl transpeptidase and mean corpuscular volume
Authors: M. J. Eckardt
Journal: JAMA (1981)

Quadratic discriminant analysis was conducted between 121 medically documented male alcoholics who presented for treatment and 130 male nonalcoholic outpatients who were concerned about the possibility of venereal disease. Analysis of γ-glutamyl transpeptidase (GGT) and mean corpuscular volume (MCV) resulted in correct classification of 94% of nonalcoholics but only 36% of alcoholics. In contrast, analysis of 24 commonly ordered clinical laboratory tests produced correct classification of 100% of nonalcoholics and 98% of alcoholics. Transforming the laboratory-determined values to a normal-abnormal dichotomy on the basis of reference values improved the classification accuracy of GGT and MCV to 77%. However, consideration of ten of the other tests resulted in an accuracy of 98% for alcoholics and 95% for nonalcoholics. (<i>JAMA</i>1981;246:2707-2710)
The Elderly Hemophiliac
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Berson, Yalow, and the JCI: the agony and the ecstasy
Authors: C. R. Kahn
Journal: Journal of Clinical Investigation (2004)

The isolation of insulin in 1921 by Banting, Best, Collip, and Macleod stands as one of the most dramatic stories in modern medical investigation. Only two years passed between the initial experiments in dogs to widespread human application to the awarding of the Nobel Prize in 1923. Insulin-related research has also served as a focus, at least in part, for the work of three other Nobel Prize recipients: determination of the chemical structure of insulin by Frederick Sanger in 1958; determination of the three-dimensional structures of insulin and vitamin B12 by Dorothy Hodgkin in 1964; and finally, the development of immunoassay by Solomon Berson and Rosalyn Yalow in 1959–1960, which led to a Nobel Prize for Yalow in 1977 (five years after the untimely death of Berson). The history of Yalow and Berson’s discovery and its impact on the field is an illustration of the adage that every story has two sides.
Author Index Vol. 63, No. 2,1995 / Subject Index Vol. 63, No. 2,1995
Authors: Harald J. Freyberger, Wolfgang Schneider, W. Schneider, G. Heuft, H.J. Freyberger, P.L. Janssen, Juan E. Mezzich, Margit M. Schmolke, Rolf-Dieter Stieglitz, Gerhard Schüssler, H.J. Freyberger, W. Schneider, C.P. Malchow, Aribert Muhs, Christina Öri, Günter Jantschek, Klaus Rodewig, Jörn von Wietersheim, Aribert Muhs, W. Ehlers, R. Hettinger, G. Paar
Journal: Psychotherapy and Psychosomatics (1995)
Letter: The aflatoxin-hepatoma-HBAg story.
Authors: John Mcgilchrist
Journal: BMJ (1975)

scribing.Too mnany clinicians go into print on insufficient evidence when they have a single case.These are taken up and per- petuated by those who write articles on MAOIs as fact.A confused situation is being compounded by inaccurate and nmisleading evidence where factual and clear authoritative reporting is required for the guidance of both the doctor and the paticnt.-I am, etc.,
Clinical-Pathological Correlations
Authors: Cases Rd Gascoyne, J Delabie, C De Wolfe-Peeters, B Skinnider, G Delsol, M Tiemann, C Schrader, M Dreyling, W Hidderaann, R Parwaresch', K Naresh, V Srinivas, C Soman, C Lagorce-Pages, A Le Tourneau, A Delmer, N Mounier, V Meignin, E Lepage, P Gaulard, C Gisselbrecht, J Diebold
Journal: Annals of Oncology (1999)
Treatment patterns among patients with advanced/recurrent endometrial cancer in the United States.
Authors: Eric M. Maiese, Bruno Émond, Jinan Liu, Marie-Hélène Lafeuille, Patrick Lefebvre, Isabelle Ghelerter, Caterina Wu, Jean Hurteau, Premal H. Thaker
Journal: Journal of Clinical Oncology (2021)

e18693 Background: Among patients (pts) with endometrial cancer (EC), response rates for platinum-based regimens in the first-line (1L) setting range from 40% to 62% in clinical trials. This study describes patient characteristics, treatment patterns, time to next treatment (TTNT), and overall survival (OS) among pts with advanced/recurrent EC treated with a platinum-based regimen in a real-world setting in the US. Methods: This retrospective study used Optum Clinformatics Extended Data Mart de-identified databases from January 1, 2007, to December 31, 2019. Adult pts with advanced/recurrent EC who initiated a 1L platinum-based regimen and subsequently initiated second-line (2L) antineoplastic therapy were identified. Prior to initiation of 1L, a 12-month washout period of continuous enrollment without use of antineoplastic agents (except hormonal agents) was imposed. Kaplan-Meier (KM) rates were used to report TTNT and OS from 2L, third line (3L), and fourth line (4L), separately. Results: A total of 1878 pts with advanced/recurrent EC initiated 2L therapy following a platinum-based regimen in 1L. Among them, 739 (39.4%) pts initiated 3L and 330 (17.6%) initiated 4L or later (4L + ) therapy. Median pt age was 68.0 years. More pts received platinum-based regimens (56.4%) in 2L than other options (Table). Few pts (3.3%) received immunotherapy. Among pts receiving 3L, a similar percentage of pts were treated with platinum-based (33.2%) and other chemotherapy regimens (33.8%); few pts received immunotherapy (3.0%). Among pts receiving 4L + , the most frequent treatment option was other chemotherapy (46.1%). Median TTNT was 17.7, 10.6, and 8.4 months for 2L, 3L, and 4L pts, respectively. KM rates of OS following initiation of 2L therapy at 1, 2, 3, and 4 years were 68.4%, 49.6%, 41.3%, and 33.6%, respectively, with a median OS of 23.5 months. Conclusions: Among pts with advanced/recurrent EC treated with platinum-based therapy in 1L, platinum-based regimens remain prevalent treatment choices in later lines of therapy. In this study, immunotherapy was used infrequently in 2L, 3L, and 4L+. The median TTNT decreased in later lines of therapy. This study highlights a critical need for novel, more effective treatment options in later lines of therapy to optimize outcomes among pts with advanced/recurrent EC.[Table: see text]
Transactions of the Arizona Medical Association.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nephrotic syndrome after use of trimethadione and paramethadione in petit mal
Authors: W. Heymann
Journal: JAMA (1967)

Because 26 cases of a nephrotic syndrome believed to be due to the administration of oxazolidinedione derivatives have been recorded since 1960, the prevention, incidence, and treatment are reviewed. Frequent urine examinations for proteinuria are recommended during the treatment of petit mal with trimethadione and paramethadione. Discontinuation of treatment in the early stages of ensuing renal disease has usually resulted in spontaneous clearance of the renal complications. Four deaths have been reported. Steroid therapy may be justified, but its effectiveness has not been proved. The histopathologic changes and symptoms in the idiopathic and this druginduced form of the nephrotic syndrome do not appear to differ except that the renal complications caused by oxazolidinedione derivatives do not tend to recur once a complete remission has been achieved unless therapy is resumed.
Mycoplasma pneumoniae pneumonia in an urban area. Five years of surveillance
Authors: H. M. Foy
Journal: JAMA (1970)

Incidence of Mycoplasma pneumoniae pneumonia was studied in a large medical cooperative in Seattle from 1963 through 1968. Twenty percent of all pneumonia was associated with M pneumoniae infection. The disease was endemic and without seasonal fluctuation during the last and the first two years of study. An epidemic started late in 1965 and peaked in January 1967. Children 5 to 9 years old consistently had the highest attack rate, while the proportion of all pneumonia due to M pneumoniae was highest among teenagers. Patients with M pneumoniae had higher rates of headache, fever, sore throat, skin rash, and ear complications, but lower rates of coryza and leukocytosis than patients with pneumonia of other etiologies. Duration of illness increased with age. Treatment with tetracyclines and erythromycin reduced the length of illness, but not the antibody response. Follow-up examinations revealed no serious sequelae.
Carcinoma of the breast. Stage II--irradiation range. Does simple mastectomy followed by radiation offer survival comparable to radical procedures?
Authors: S. Kaae
Journal: JAMA (1967)

During the past two decades many hospitals have been increasing the use of radiotherapy in breast cancer in operable stages. The most widespread method is simple mastectomy followed by irradiation. This method has been systematized mainly by McWhirter,<sup>16</sup>who uses it in all cases of operable breast cancer and in a number of inoperable cases, too. His therapeutic results are good, but a reliable comparison of his own results with those of radical mastectomy has not been possible. McWhirter states that the therapeutic results of radical mastectomy are excellent when the axillary nodes are not involved, but if there are no malignant cells in the axilla it would appear unnecessary to dissect it. On the other hand, when the axilla is secondarily involved, there is universal agreement that radical mastectomy often fails to save the patient's life. It is generally agreed that the prognosis following radical mastectomy in cases
Hepatitis B virus mutations in the pre-S genome before and after liver transplantatio
Authors: C Trautwein
Journal: Hepatology (1996)

Mutational changes in the pre-S region of hepatitis B virus (HBV) were analyzed in 20 patients who experienced HBV reinfection after orthotopic liver transplantation (OLT). HBV DNA was extracted from patient sera before and after OLT. The pre-S sequence was amplified via polymerase chain reaction, subcloned, sequenced, and analyzed. In 18 of 20 patients, mutational changes were found in the pre-S region pre- or post-OLT; 11 showed point mutations (1-10) and 7 cases major changes (insertions/deletions). For the point mutations, there was no trend in the selection of wild-type (wt) HBV before or after OLT in the pre-S region. Additional HBV reinfection during hepatitis B surface antigen antibody (anti-HBS) administration had no influence on selection pressure in the pre-S region. In contrast, insertions/deletions were more frequently found before OLT. In the 7 patients with deletions/insertions, changes in the hepatocyte attachment site were not seen after OLT. Interestingly, the only patient with changes in a major virus population after OLT had changes in the CCAAT-box of the S-promoter. As shown by gel shift analysis, this mutation was associated with loss of specific binding to this element and thus probably led to dysregulation of S-gene transcription. Major changes in the pre-S genome are mainly seen before OLT, and HBV reinfection does occur with the intact hepatocyte attachment sites after OLT. Anti-HBs (hepatitis B immune globulin [HBIg]) creates no selection pressure on the pre-S region. The mutation in the CCAAT-box of the S-promoter potentially leads to its dysregulation and may be associated with the occurrence of fibrosing cholestatic hepatitis after OLT.
Landfills: is wetter better?
Journal: Environmental Health Perspectives (1998)

Forumproperties that might be expected to lead to endocrine disruption in an intact organism or its progeny or subpopulations.The global inventory of research on endocrine disruptors is intended to serve as a communications tool, providing infor- mation exchange among scientists worldwide.This will allow for the examination of current research efforts, and aid in iden-
The Cover
Authors: Ian M. Williamson
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patient History Under Scrutiny
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Preventive medicine and public health
Authors: W. Foege
Journal: JAMA (1994)

Some things are best seen from a distance. Focusing on the major developments of preventive medicine and public health in the past year forces consideration of hantavirus, national health system reform, tracking systems for immunization, the first month without measles in the history of this country, and the like. However, a deliberate attempt to list the major public health developments of the past quarter century made it clear that one of them happens to be a development of recent years and, in addition, is undervalued or even unrecognized, even in public health circles. What is this and what are some of the other major contributions of the last 25 years? The first is the attempt to plan a rational public health future for the United States. It began in 1978 with a US Public Health Service effort to develop objectives for the year 1990.<sup>1</sup>The effort began in meetings
Patient care in nursing homes. A look at responsibility
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect References
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal